Insider Trading Activity in: Pluristem Therapeutics (PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) insider has recently participated in insider trading activity. CEO & Chairman, Aberman Zami bought 15,000 shares for $ 15,990 via one transaction Feb 16. Another notable insider trading was done by YANAY YAKY on Feb 16, who is the CFO, COO & President. The insider acquired 15,000 shares at an average price of $0.95. Moreover, an insider selling of 12,346 shares was carried out by SHORRER DORON, SHORRER DORON, on Feb 15. Following the transaction, the insider now owns 582,554      shares in total. CFO, COO & President YANAY YAKY bought 5,000 shares for $ 4,139 through one transaction Feb 12. Following this sale, this insider’s stake in the company comprises 46,499    shares, priced at $59983.71 as of Wednesday.

The stock has experienced a total of 15 insider trades in the past three months. These trades include 0 sell activities and 15 buy trades. Furthermore, over the past 12 months, the stock was traded 25 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in just 24 instances.

Pluristem Therapeutics Inc. (PSTI) a leading developer of placenta-based cell therapy products, announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical counter measure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS). Once the optimal dose is determined in large animals, a pivotal trial could be conducted and the results used to support a Biologics License Application (BLA) submission of PLX-R18 for this indication under the Animal Rule regulatory pathway. In September 2015, the FDA had confirmed that data from earlier trials conducted by NIAID were sufficient for the future design of studies in Pluristem’s development path for PLX-R18. NIAID is supporting and collaborating on the dosing studies, and Pluristem is supplying PLX-R18.

ARS is caused by exposure to very high levels of radiation, such as those that could occur in a nuclear catastrophe. The syndrome can cause severe illness or death. When human trials are not ethical or feasible, as in this indication, the FDA’s Animal Rule regulatory pathway allows for the determination of the efficacy of drugs using animal efficacy studies and human safety data.